|drug4093||Triazavirin (Riamilovir) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.
Description: defined as the time from first dose of polyphenol extract to hospital dischargeMeasure: Time to hospital discharge Time: Throughout the Study (Day 0 to Day 28)
Description: proportionMeasure: 28-day all-cause mortality Time: Throughout the Study (Day 0 to Day 28)
Description: proportionMeasure: invasive ventilation on day 28 Time: Throughout the Study (Day 0 to Day 28)
Description: mean differenceMeasure: Difference in Pro and antiinflammatory citoquine levels Time: day 1-14
Description: proportionMeasure: Negativization of COVID-PCR at day 14 Time: day 14
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports